Salute e Benessere

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 14 November 2023— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and...
Nasdaq GlobeNewswire
14/11/2023

Nexstim Receives First Order for NBS 6 Therapy System in the United States

Press release, Helsinki, 14 November 2023, at 12:30 PM (EET) Nexstim Receives First Order for NBS 6 Therapy System in the United States Nexstim Plc (NXTMH:HEX) (“ Nexstim ” or “ Company ”) announces that its' US subsidiary, Nexstim, Inc. has received the first order for a new NBS 6 therapy system. Nexstim will deliver the NBS System 6 and support services to a private clinic located in North Carolina, United States.The NBS 6 is a new generation Nexstim system that was released in the...
Nasdaq GlobeNewswire
14/11/2023

Coloplast A/S - Notice of Annual General Meeting 2023

The Annual General Meeting of Coloplast A/S will be held onThursday, 7 December 2023 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark.The notice of the Annual General Meeting is enclosed. For further information, please contactInvestors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111Aleksandra Dimovska Senior Director, Investor Relations Tel. +45 4911 1800...
Nasdaq GlobeNewswire
14/11/2023

AQUALITAS LEADS THE WAY AS THE FIRST ORGANIC CANNABIS PRODUCER IN THE WORLD TO…

"The successful attainment of EU-GMP Certification reflects the extraordinary efforts of our quality and operations teams in their persistent and patient pursuit of this important goal", noted Danielle Maitland, Director of Science and Cultivation Technology, who along with Dorothy Easy, Quality Assurance Person, and Nicholas Vorauer, Lead Extraction Scientist, spearheaded the EU-GMP and DEL compliance initiatives. "The successful attainment of EU-GMP Certification reflects the…
PR Newswire
14/11/2023

Natura &Co: Consistent adjusted EBITDA margin improvement alongside strengthened…

Natura &Co's Q3 consolidated net revenue stood at R$ 7.5 billion, broadly stable at constant currency (-0.7% at CC and -10.5% in BRL), with the Natura brand posting strong growth in Brazil and Latin America. Gross margin grew by 310 bps vs Q3 of last year to 65.3%, and adjusted EBITDA margin was 10%, up 190 bps vs the same period last year, reflecting improving margins in all three business units, Natura &Co Latam, Avon International and The Body Shop, as well as cost discipline…
PR Newswire
14/11/2023

Cardiac Biomarker Market worth $38 billion by 2033 - Exclusive Report by We…

The cardiac biomarker industry is experiencing a transformative wave, driven by notable technological advancements that have illuminated new and highly profitable avenues within the sector. These technological innovations are not only reshaping the landscape of cardiac diagnostics but also offering a wealth of opportunities for stakeholders, including healthcare professionals, researchers, and patients. The cardiac biomarker industry is experiencing a transformative wave, driven by notable...
PR Newswire
14/11/2023

Winners of the 2024 Rank Prize for Nutrition Announced

Professor Roy Taylor and Professor Mike Lean are the winners of the 2024 Rank Prize for Nutrition. Their research has furthered understanding of how type 2 diabetes develops, and has shown for the first time that remission from type 2 diabetes is possible for some by following a low-energy weight management programme. Their research is transforming services for people newly diagnosed with type 2 diabetes by giving them the support to manage their health and reverse the effects of this serious…
PR Newswire
14/11/2023

Ergomed strongly positioned for future growth in new partnership with Permira

PRESS RELEASEErgomed strongly positioned for future growthin new partnership with Permira Permira completes acquisition of Ergomed for £703.1 millionThrough this partnership, Permira will support Dr. Miroslav Reljanović and the team in Ergomed's next phase by accelerating the growth of the businessInvestment to focus on commercial expansion, technology and strategic M&AGuildford, UK and London, UK – 14 November 2023:Ergomed plc (" Ergomed ") and Permira...
Nasdaq GlobeNewswire
14/11/2023

Implantica takes a big step forward at its 2nd Annual RefluxStop™ Users Meeting

Current, past and upcoming Presidents of the medical societies EFS (European Foregut Society) and AFS (American Foregut Society) were in attendance, including several Board members. Current, past and upcoming Presidents of the medical societies EFS (European Foregut Society) and AFS (American Foregut Society) were in attendance, including several Board members. Significant highlights of the day included real-world data on nearly 600 treated patients, excellent long-term patient outcomes from...
PR Newswire
14/11/2023

SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE…

SENISCA strengthens Board with the appointment of Dr. David Chiswell, Ph.D, OBE as Chairman Highly experienced biotech veteran to support SENISCA's rapid development of its senotherapeutic platformExeter, UK — 14 November 2023:SENISCA SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and treat age-related disease, today announces the appointment of Dr. David Chiswell Ph.D, OBE as Chairman of the Board.Dr. David Chiswell is one of the...
Nasdaq GlobeNewswire
14/11/2023

BerGenBio Reports Third Quarter 2023 Financial Results

Clinical Development Clinical Development Bemcentinib BerGenBio's lead compound,bemcentinib, is a potentially first-in-class, oral, highly selective inhibitor of the receptor tyrosine kinase AXL, which is expressed and activated in response to oxidative stress, inflammation, hypoxia and drug treatment, resulting in several deleterious effects in cancer and severe respiratory infections.Bemcentinibselectively inhibits AXL activation to prevent the progression of serious...
PR Newswire
14/11/2023

Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Top line results expected in Q2 2024 Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, November 14, 2023 - Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the last patient has been randomized in Cohort 2 of the ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study. Results evaluating the efficacy, safety and tolerability of ADX71149 in...
Nasdaq GlobeNewswire
14/11/2023

Pixium Vision announces the 48-Month Trial Results in Severe Atrophic AMD

Pixium Vision announces the 48-Month Trial Results in Severe Atrophic AMDStudy confirms subretinal prothesis feasible and well-tolerated with no reduction of natural peripheral vision, confirming 36-month results Patients suffering from central vision loss reliably recognized letters and sequences of letters, a clinically significant improvementFull data readout of accompanying pivotal PRIMAvera trial expected early 2024Pixium Vision reiterates that it is subject to...
Nasdaq GlobeNewswire
14/11/2023

Roche's subcutaneous injection of Tecentriq recommended by the EU's CHMP for…

If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80% 1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer 2 A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV 1 Basel,...
Nasdaq GlobeNewswire
14/11/2023

HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and…

"I'm immensely proud to have served as HaemaLogiX's CEO for the past 8 years, during which time we have focused the strategic direction of the company on development of our portfolio from a single immunotherapy asset to potentially seven products, with two now in clinical stages," Mr Carmine said. "I congratulate Damian on his appointment, and I look forward to working together to further build toward the successful commercialisation of the company and our products."…
PR Newswire
14/11/2023

Surgical Drapes Market to Reach $2.1 Billion, Globally, by 2032 at 3.6% CAGR…

Request Sample of the Report on Surgical Drapes Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/3796 Request Sample of the Report on Surgical Drapes Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/3796 Prime determinants of growth Growth in R&D activities, rise in prevalence of chronic conditions that require surgical interventions, and rise in awareness regarding the use of surgical drapes to minimize contamination risk...
PR Newswire
14/11/2023

More than two in three people with diabetes already have complications at…

Diabetes-related complications can be serious and, in some cases, life-threatening. They include damage to the heart, eyes, kidneys and feet. The risk of complications places significant stress on people living with diabetes. More than half (55%) of respondents say they worry most days about developing diabetes-related complications. Diabetes-related complications can be serious and, in some cases, life-threatening. They include damage to the heart, eyes, kidneys and feet. The risk of...
PR Newswire
14/11/2023

MULTI-MILLION POUND BOOST FOR RESEARCH PROJECTS AIMED AT DEVELOPING NEW TESTS…

MULTI-MILLION POUND BOOST FOR RESEARCH PROJECTS AIMED AT DEVELOPINGNEW TESTS, TREATMENTS AND DEVICES FOR NEURODEGENERATIVE DISEASES Seven major research projects to receive more than £14 million to develop new tests, treatments and devices for neurodegenerative diseases including Alzheimer's, motor neuron disease and Parkinson's disease.The projects receiving the funding include a unique gene therapy for motor neuron disease and a form of dementia, an antibody treatment for...
Nasdaq GlobeNewswire
14/11/2023

Prader-Willi Syndrome Market is Likely to Increase at a Steady Growth Rate by…

Key Takeaways from the Prader-Willi Syndrome Market Report Key Takeaways from the Prader-Willi Syndrome Market Report Discover which therapies are expected to grab the major Prader-Willi syndrome market share @Prader-Willi Syndrome Market Report Prader-Willi Syndrome Overview Prader-Willi syndrome (PWS) is a genetic disorder characterized by distinct stages of symptoms. In early infancy, affected individuals typically display severe muscle weakness (hypotonia), feeding...
PR Newswire
13/11/2023

Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC…

ELATIVE ®Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR α,δ agonist for patients with primary biliary cholangitis.Elafibranor demonstrates significant improvements in biomarkers of disease progression versus placebo, including significant treatment benefit with improvement in biochemical response and alkaline phosphatase (ALP) normalization, along with patient-reported outcomes data suggesting a possible improvement in pruritus...
Nasdaq GlobeNewswire
13/11/2023

GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in…

ELATIVE® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR α,δ agonist for patients with Primary Biliary Cholangitis.Elafibranor demonstrates significant improvements in biomarkers of disease progression versus placebo, including significant treatment benefit with improvement in biochemical response and alkaline phosphatase (ALP) normalization, along with patient-reported outcomes data suggesting a possible improvement in pruritus...
Nasdaq GlobeNewswire
13/11/2023

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR316.9 months median progression free survival (mPFS) and 23.1 months median overall survival (mOS) following radiotherapy-activated (RT) NBTXR3 in topline Study 102 Phase 1 data in head and neck cancer strengthens hypotheses for pivotal NANORAY-312 trial designPromising initial anti-tumor efficacy, median overall survival (mOS) of 23 months, 92% local...
Nasdaq GlobeNewswire
13/11/2023

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for…

SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentationat American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data supporting potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders presented at World Sleep Congress; Advancing in IND-enabling studies; Clinical proof of concept data planned...
Nasdaq GlobeNewswire
13/11/2023

MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding…

NEWS RELEASE - REGULATED INFORMATION INSIDE INFORMATION NOVEMBER 13, 2023 , 4:00 PM ET / 22:00 CETMDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting RightsIRVINE, CA, and HERSTAL, BELGIUM– November 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today announces that it completed the share consolidation with respect to all its outstanding...
Nasdaq GlobeNewswire
13/11/2023
Altri  Comunicati